These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 12604433)

  • 1. Immune thrombocytopenia induced by fludarabine successfully treated with rituximab.
    Fernandez MJ; Llopis I; Pastor E; Real E; Grau E
    Haematologica; 2003 Feb; 88(2):ELT02. PubMed ID: 12604433
    [No Abstract]   [Full Text] [Related]  

  • 2. [Successful combined treatment with rituximab and high dose immunoglobulin in a patient with chronic lymphocytic leukemia with fludarabine-induced severe immune thrombocytopenia].
    Telek B; Batár P; Uvardy M
    Orv Hetil; 2005 Aug; 146(34):1791-3. PubMed ID: 16184881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fludarabine-associated autoimmune hemolytic anemia occurring in B-cell chronic lymphocytic leukemia.
    Nishida H; Murase T; Ueno H; Park JW; Yano T; Ikeda Y
    Leuk Res; 2006 Dec; 30(12):1589-90. PubMed ID: 16542723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of lymphoma with fludarabine combined with rituximab after immune thrombocytopenia induced by fludarabine.
    Tsutsumi Y; Kanamori H; Minami H; Musashi M; Fukushima A; Ehira N; Yamato H; Obara S; Ogura N; Tanaka J; Asaka M; Imamura M; Masauzi N
    Ann Hematol; 2005 Apr; 84(4):269-71. PubMed ID: 15592832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variations on the fludarabine, cyclophosphamide, and rituximab combination in chronic lymphocytic leukemia therapy: what have we learned?
    Ahmadi T; Schuster SJ
    J Clin Oncol; 2009 Feb; 27(4):479-80. PubMed ID: 19075263
    [No Abstract]   [Full Text] [Related]  

  • 6. Fludarabine-induced autoimmune hemolytic anemia in a CLL patient: rituximab as the treatment of choice?
    Smolej L
    Leuk Res; 2007 Feb; 31(2):267; author reply 268-9. PubMed ID: 16716397
    [No Abstract]   [Full Text] [Related]  

  • 7. Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia.
    Hegde UP; Wilson WH; White T; Cheson BD
    Blood; 2002 Sep; 100(6):2260-2. PubMed ID: 12200396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of refractory fludarabine induced autoimmune haemolytic with the anti-CD20 monoclonal antibody rituximab.
    Swords R; Nolan A; Fay M; Quinn J; O'Donnell R; Murphy PT
    Clin Lab Haematol; 2006 Feb; 28(1):57-9. PubMed ID: 16430461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fludarabine induced immune thrombocytopenia in a patient with CD5 positive B cell chronic lymphocytic leukemia.
    Usman M; Adil SN; Sajid R; Khurshid M
    J Pak Med Assoc; 2003 Oct; 53(10):496-7. PubMed ID: 14696895
    [No Abstract]   [Full Text] [Related]  

  • 10. Cerebral toxoplasmosis in a patient with chronic lymphocytic leukaemia treated with fludarabine.
    Bacchu S; Fegan C; Neal J
    Br J Haematol; 2007 Nov; 139(3):349. PubMed ID: 17784883
    [No Abstract]   [Full Text] [Related]  

  • 11. Paraneoplastic pemphigus despite treatment with rituximab, fludarabine and cyclophosphamide in chronic lymphocytic leukemia.
    Schierl M; Foedinger D; Geissler K; Rappersberger K; Feldmann R
    Eur J Dermatol; 2008; 18(6):717-8. PubMed ID: 19049939
    [No Abstract]   [Full Text] [Related]  

  • 12. Fludarabine for chronic lymphocytic leukemia.
    Copur MS; Ledakis P; Muhvic J
    N Engl J Med; 2001 Apr; 344(15):1166; author reply 1167-8. PubMed ID: 11302141
    [No Abstract]   [Full Text] [Related]  

  • 13. Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies.
    Tam C; Seymour JF; Brown M; Campbell P; Scarlett J; Underhill C; Ritchie D; Bond R; Grigg AP
    Haematologica; 2005 May; 90(5):700-2. PubMed ID: 15921393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor lysis syndrome associated with fludarabine treatment in chronic lymphocytic leukemia.
    Dizdar O; Yürekli BS; Pürnak T; Aksu S; Haznedaroglu IC
    Ann Pharmacother; 2004; 38(7-8):1319-20. PubMed ID: 15138295
    [No Abstract]   [Full Text] [Related]  

  • 15. Evan's syndrome precipitated by fludarabine therapy in a case of CLL.
    Sen K; Kalaycio M
    Am J Hematol; 1999 Jul; 61(3):219. PubMed ID: 10398320
    [No Abstract]   [Full Text] [Related]  

  • 16. A phase II trial of fludarabine in patients with previously treated chronic lymphocytic leukaemia.
    Hocepied AM; Falkson CI; Falkson G
    S Afr Med J; 1996 May; 86(5):549-50. PubMed ID: 8711555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fludarabine therapy in chronic lymphocytic leukemia-associated severe nephrotic syndrome.
    Abdel-Raheem MM; Jamil MG; Potti A; Gross GG
    Haematologica; 2000 Nov; 85(11):1224-5. PubMed ID: 11064479
    [No Abstract]   [Full Text] [Related]  

  • 18. Severe autoimmune hemolytic anemia following fludarabine therapy in a patient with chronic lymphocytic leukemia.
    Tsiara S; Christou L; Konstantinidou P; Panteli A; Briasoulis E; Bourantas KL
    Am J Hematol; 1997 Apr; 54(4):342. PubMed ID: 9092698
    [No Abstract]   [Full Text] [Related]  

  • 19. Fludarabine-induced eosinophilia: case report.
    Voutsadakis IA
    Ann Hematol; 2002 May; 81(5):292-3. PubMed ID: 12029541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute tumor lysis syndrome during oral fludarabine treatment for CLL--a rare event that might be observed more frequently in the future.
    Rioufol C; Coiffier B
    Onkologie; 2008 Apr; 31(4):157-8. PubMed ID: 18418014
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.